» Articles » PMID: 37836411

Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy

Overview
Journal Nutrients
Date 2023 Oct 14
PMID 37836411
Authors
Affiliations
Soon will be listed here.
Abstract

The pathophysiology of chronic kidney disease-mineral and bone disorder (CKD-MBD) is not well understood. Specific factors secreted by osteocytes are elevated in the serum of adults and pediatric patients with CKD-MBD, including FGF-23 and sclerostin, a known inhibitor of the Wnt signaling pathway. The molecular mechanisms that promote bone disease during the progression of CKD are incompletely understood. In this study, we performed a cross-sectional analysis of 87 pediatric patients with pre-dialysis CKD and post-dialysis (CKD 5D). We assessed the associations between serum and bone sclerostin levels and biomarkers of bone turnover and bone histomorphometry. We report that serum sclerostin levels were elevated in both early and late CKD. Higher circulating and bone sclerostin levels were associated with histomorphometric parameters of bone turnover and mineralization. Immunofluorescence analyses of bone biopsies evaluated osteocyte staining of antibodies towards the canonical Wnt target, β-catenin, in the phosphorylated (inhibited) or unphosphorylated (active) forms. Bone sclerostin was found to be colocalized with phosphorylated β-catenin, which suggests that Wnt signaling was inhibited. In patients with low serum sclerostin levels, increased unphosphorylated "active" β-catenin staining was observed in osteocytes. These data provide new mechanistic insight into the pathogenesis of CKD-MBD and suggest that sclerostin may offer a potential biomarker or therapeutic target in pediatric renal osteodystrophy.

Citing Articles

Evaluation of Bone Biomarkers in Renal Osteodystrophy.

Pichone A, Gomes C, Moreira C, Farias M, Leite Jr M Life (Basel). 2025; 14(12.

PMID: 39768249 PMC: 11679507. DOI: 10.3390/life14121540.

References
1.
Sabbagh Y, Graciolli F, OBrien S, Tang W, Dos Reis L, Ryan S . Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27(8):1757-72. DOI: 10.1002/jbmr.1630. View

2.
Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M . Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone. 2014; 66:182-8. DOI: 10.1016/j.bone.2014.06.015. View

3.
Bakkaloglu S, Wesseling-Perry K, Pereira R, Gales B, Wang H, Elashoff R . Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010; 5(10):1860-6. PMC: 2974387. DOI: 10.2215/CJN.01330210. View

4.
Huybrechts Y, Evenepoel P, Haarhaus M, Cavalier E, Dams G, Van Hul W . Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover. Nutrients. 2023; 15(3). PMC: 9921466. DOI: 10.3390/nu15030598. View

5.
Guven S, Gokce I, Cicek N, Yaman A, Vatansever P, Alpay H . Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children. J Pediatr Endocrinol Metab. 2020; 33(11):1383-1390. DOI: 10.1515/jpem-2020-0140. View